Also, Telisotuzumab vedotin (Teliso-V), c‐Met protein-targeted ADC, is being evaluated in MET-overexpressing and EGFR-mutant resistant NSCLC [263, 264]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.